HIV and Long COVID: Understanding the Compounding Risks

Introduction

As the acute crisis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has transitioned into an endemic reality, the focus of the global medical and scientific communities has increasingly shifted toward the chronic sequelae of the infection. Post-acute sequelae of SARS-CoV-2 (PASC), widely referred to as Long COVID, has emerged as a complex, heterogeneous, and debilitating condition that currently affects tens of millions of people worldwide. Characterized by a constellation of over two hundred diverse symptoms that persist for months or even years following the resolution of the acute infection, Long COVID impacts multiple organ systems, resulting in profound physiological, respiratory, and neurocognitive impairments.¹ For the general population, the burden of Long COVID is substantial and growing, but for marginalized and medically complex populations—specifically people living with human immunodeficiency virus (HIV)—the intersection of a novel respiratory virus with a pre-existing chronic viral infection presents unique, magnified, and highly specific risks.

People living with HIV represent a highly vulnerable demographic in the context of the COVID-19 pandemic. Historically, the advent of antiretroviral therapy transformed HIV from a fatal diagnosis into a manageable chronic condition. However, the underlying immunological scars of the initial infection remain permanently etched into the host's biology. Even when viral replication is fully suppressed by modern therapeutics, HIV induces a state of persistent immune activation, chronic systemic inflammation, and cellular exhaustion. When a novel pathogen like SARS-CoV-2 is introduced into this already dysregulated immunological environment, the potential for prolonged complications and aberrant immune responses is significantly heightened. Current epidemiological data suggest that people living with HIV face a markedly elevated risk of developing Long COVID compared to the general population, with symptoms often presenting more severely and persisting for longer durations.²

Understanding the relationship between HIV and Long COVID requires a multidimensional analytical approach. It necessitates a thorough examination of large-scale epidemiological trends across global databases, a deep dive into the cellular pathobiology of T-cell exhaustion and inflammasome activation, an exploration of viral persistence within tissue reservoirs, and an evaluation of the complex gut-systemic axis. Furthermore, translating these complex biological insights into effective clinical management requires adaptive healthcare models capable of navigating overlapping diagnostic criteria and addressing profound health inequities. This comprehensive report provides an exhaustive synthesis of the current research surrounding the intersection of HIV and Long COVID, detailing the epidemiological evidence, unpacking the specific biological mechanisms that drive this unique vulnerability, and outlining the clinical implications for long-term patient care and rehabilitative strategy.

The Epidemiological Landscape of Long COVID in HIV

The epidemiological data establishing a definitive link between HIV infection and an increased risk of Long COVID has grown increasingly robust over the past several years. This evidence is driven by large-scale retrospective cohort studies, global meta-analyses, and deep data-mining of electronic health records. These investigations not only quantify the overall elevated risk but also illuminate the specific organ systems that are most susceptible to post-acute damage in people living with HIV.

Cohort Studies and Organ System Vulnerabilities

One of the most comprehensive investigations into this intersection was published in the Journal of Acquired Immune Deficiency Syndromes by a research team affiliated with the University of South Carolina Arnold School of Public Health. Utilizing integrated, statewide electronic health records, the researchers analyzed a massive cohort of 838,520 adults with confirmed COVID-19 infections, identified between the early months of the pandemic in March 2020 and January 2022.² Within this large sample, 2,662 individuals were explicitly identified as living with HIV.

The core findings of this state-wide study revealed a stark disparity in post-acute outcomes between the two groups. Overall, 16.3 percent of the individuals living with HIV received a formal Long COVID diagnosis within the standard 30- to 180-day window following their initial acute infection. In contrast, only 10.6 percent of the cohort without HIV received a similar diagnosis.² When adjusted for confounding variables such as age, sex, and baseline comorbidities, this translates to an estimated 29 percent higher overall risk of developing any Long COVID condition for people living with HIV.²

The elevated risk, however, was not distributed equally across all physiological systems. The researchers observed profound variations in susceptibility depending on the specific organ system involved, suggesting that the pathophysiology of Long COVID in this population is highly targeted. The nervous system demonstrated the most dramatic vulnerability. People living with HIV faced more than double the risk of developing neurological complications, which manifest clinically as persistent severe headaches, distinct nervous-system pain, cognitive fog, and profound sleep disruptions.²

The following table outlines the adjusted hazard ratios for various Long COVID diagnostic groups among people living with HIV compared to the general population, illustrating the systemic breadth of the risk ²:

Organ System / Diagnostic Category	Adjusted Hazard Ratio	Risk Increase
Nervous System Diseases	2.04	104 percent higher risk
Respiratory Diseases	1.78	78 percent higher risk
Mental, Behavioral, and Neurodevelopmental	1.78	78 percent higher risk
Endocrine and Metabolic Diseases	1.70	70 percent higher risk
Genitourinary Disorders	1.59	59 percent higher risk
Digestive System Diseases	1.47	47 percent higher risk
Musculoskeletal Conditions	1.45	45 percent higher risk

Notably, while the risk was significantly elevated across nearly all categories, the study found no significant difference in the risk of circulatory system disorders between the two groups.² Despite the variations in specific organ system involvement, both cohorts frequently reported overlapping generalized symptoms, including profound physical fatigue, diffuse abdominal pain, and chronic muscle and joint issues.² The study's authors emphasized the necessity of sustained follow-up for COVID-19 survivors living with HIV to improve clinical outcomes and prevent the long-term morbidity associated with these conditions.⁵

Global Meta-Analyses and Synergistic Risk Factors

Beyond individual statewide cohort studies, systematic reviews pooling data from diverse global populations further validate and expand upon these findings. A comprehensive meta-analysis incorporating seventeen eligible studies—culled from over six thousand publications across multiple databases including Embase, PubMed, and Web of Science—represented a combined total of 39,405 people living with HIV who had contracted COVID-19.⁴ The researchers estimated that an alarming 52 percent of this specific population developed at least one Long COVID symptom following a SARS-CoV-2 infection.⁴ The random-effects statistical model generated from this extensive analysis produced an overall odds ratio of 2.20, indicating that HIV infection more than doubles the likelihood of developing post-acute sequelae.⁴

The most prevalent symptoms identified in these broader global analyses align closely with the localized cohort data: chronic persistent cough, debilitating fatigue, and asthenia, a medical term denoting abnormal physical weakness or lack of energy.⁴ Crucially, the meta-analysis identified specific clinical risk factors within the HIV-positive population that act as strong predictors for the onset of Long COVID. A history of moderate-to-severe acute COVID-19 illness, specifically cases whose severity required hospitalization, was strongly correlated with a significantly increased risk of developing Long COVID.⁴

Furthermore, virological and immunological markers specific to the underlying HIV infection played a critical role in predicting outcomes. Individuals with higher HIV viral loads, specifically those carrying greater than 20 copies per milliliter of blood, were found to have lower levels of both Immunoglobulin M and Immunoglobulin G antibody responses compared to individuals with fully suppressed viral loads.⁴ While absolute CD4-positive T-lymphocyte counts did not always directly correlate with antibody responses in every study, broadly speaking, individuals with low levels of CD4-positive T-lymphocytes demonstrated a weaker ability to produce protective antibodies.⁴ This compromised humoral response leaves these individuals more susceptible to prolonged viral activity and the subsequent development of chronic symptoms.⁴ The review notes that vulnerability to Long COVID is often exacerbated by a synergy of sociodemographic factors, medical comorbidities, and the fundamental dysregulation of immunological systems.⁴

The Diagnostic Paradox: Computed Phenotypes vs. Clinical Codes

While the epidemiological evidence strongly supports an increased risk of Long COVID in people living with HIV, translating this risk into accurate clinical diagnoses and prevalence tracking remains a significant structural challenge. This complexity is best illustrated by findings from the Researching COVID to Enhance Recovery (RECOVER) Initiative, a massive multi-center program analyzing health data across the United States.⁸

The RECOVER researchers utilized data from two massive electronic health record databases: the Patient-Centered Clinical Research Network (PCORnet) and the National Clinical Cohort Collaborative (N3C). The scope of this analysis was vast, covering the period from January 2018 to April 2024 and including over 4.6 million patients who had contracted SARS-CoV-2.⁸ The findings of this massive study varied significantly depending on the specific methodology and definition used to identify Long COVID within the medical records.

When the researchers utilized a "computed phenotype"—a sophisticated computer algorithm designed to scan medical records and identify patterns of Long COVID symptoms regardless of whether an official diagnosis code was present—they found a modest but statistically significant increase in the risk of Long COVID for people living with HIV.⁸ In the PCORnet cohort, which included 1,369,896 patients (11,964 with HIV), the adjusted odds ratio was 1.09. In the N3C cohort, which included 3,312,355 patients (23,931 with HIV), the adjusted odds ratio was 1.18.⁸

However, when the researchers restricted their definition strictly to the official International Classification of Diseases, Tenth Revision (ICD-10) diagnostic code for Long COVID, the statistical association vanished completely. Under this strict coding definition, there was no significant association found between HIV status and the condition, with adjusted odds ratios hovering near 1.0.⁸

This stark discrepancy highlights a profound issue of underrecognition and diagnostic overshadowing in the clinical setting. The researchers concluded that the discrepancy between the phenotype findings and the ICD-10 code findings suggests that Long COVID is frequently missed or miscategorized in people living with HIV.⁸ In populations burdened with baseline chronic conditions like HIV, clinicians may erroneously attribute new or persistent symptoms—such as fatigue, neurocognitive fog, or generalized pain—to the underlying HIV infection, the side effects of antiretroviral therapy, or aging, rather than recognizing them as a distinct post-viral syndrome.⁸ This diagnostic masking not only prevents accurate epidemiological tracking but also severely delays appropriate rehabilitative care and resource allocation for patients.

Immunological Drivers and Cellular Pathobiology

The heightened susceptibility of people living with HIV to Long COVID cannot be attributed merely to the simple additive effects of experiencing two infections simultaneously. Rather, it is the result of a complex, synergistic interaction between the viruses and the host's innate and adaptive immune systems. To fully grasp this vulnerability, it is necessary to examine the foundational state of the immune system in people living with HIV and detail how SARS-CoV-2 exploits these pre-existing weaknesses through specific biological mechanisms, notably T-cell exhaustion and inflammasome overactivation.

Baseline Immune Dysregulation and Chronic Inflammation

The defining hallmark of an untreated HIV infection is the progressive depletion of CD4-positive T cells and the subsequent eventual collapse of cell-mediated immunity. While modern antiretroviral therapy effectively halts viral replication and allows for the numerical recovery of T cells in the blood, it does not fully reverse the profound immunological damage inflicted during the early stages of the disease. People living with HIV consistently exhibit increased baseline levels of systemic inflammation and immune dysregulation, even when clinically classified as virally suppressed and immunologically stable.³

This chronic inflammatory state is characterized by elevated circulating levels of pro-inflammatory cytokines, which are small proteins used for cell signaling. When a person living with HIV contracts SARS-CoV-2, the acute viral infection acts as a severe secondary inflammatory insult. The immune system, already primed and operating at a heightened state of alert due to the retrovirus, responds with an exaggerated inflammatory cascade.³ This pre-existing dysregulation makes it exceedingly difficult for the immune system to return to a state of baseline homeostasis after the acute SARS-CoV-2 infection resolves. The failure to resolve this inflammation sets the stage for the chronic, systemic symptoms that clinically define Long COVID.³

Furthermore, research indicates that the ratio of CD4-positive to CD8-positive T cells plays a significant role. A study analyzing immune markers found that higher CD4 to CD8 ratios were associated with lower overall frequencies of certain exhausted T cells, suggesting that the fundamental balance of immune cells dictated by the history of HIV infection directly impacts how the body manages a subsequent SARS-CoV-2 encounter.¹⁰

The Mechanics of T-Cell Exhaustion

One of the primary biological mechanisms driving the pathology of Long COVID, particularly in people living with HIV, is a cellular phenomenon known as T-cell exhaustion. In a healthy, standard immune response, T cells rapidly proliferate and execute effector functions upon encountering a novel pathogen. They secrete cytokines to recruit other immune cells, directly destroy virus-infected cells, and subsequently differentiate into long-lived memory cells that protect against future infections. However, when the immune system is subjected to prolonged, unrelenting antigenic stimulation—such as in the presence of a chronic viral infection like HIV, or in the presence of persistent remnants of SARS-CoV-2—the T cells enter a terminal state of dysfunction.¹¹

T-cell exhaustion should not be misconstrued as a simple "tiring out" of the cells. Rather, it is a distinct, transcriptionally reprogrammed state characterized by epigenetic dysregulation and altered metabolism.¹¹ Exhausted T cells progressively lose their ability to proliferate, fail to secrete vital antiviral cytokines like interferon-gamma and tumor necrosis factor-alpha, and lose the ability to release cytotoxic granules to kill infected host cells.¹¹

As part of this reprogramming, the exhausted cells begin to sustain high levels of specific inhibitory surface receptors. The most notable of these is programmed cell death protein 1 (PD-1), alongside others such as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).¹¹ In a biological context, these receptors act as emergency brakes; they are intended by the body to prevent the immune system from causing excessive autoimmune tissue damage during a chronic infection. However, the ultimate consequence is that the T cells are rendered largely ineffective at clearing the actual pathogen.¹¹

In the specific context of Long COVID, researchers analyzing blood samples have consistently observed that individuals experiencing persistent symptoms display elevated frequencies of these exhausted T cells, specifically noting persistent activation of inflammatory pathways combined with markers of immune impairment.¹³ For people living with HIV, the situation is compounded by their baseline status. Extensive profiling of the adaptive immune response has shown that people living with HIV who contract COVID-19 develop higher levels of exhausted, PD-1-positive SARS-CoV-2-specific CD4-positive T cells compared to the general population.³ Concurrently, they exhibit significantly lower levels of fully functional SARS-CoV-2-specific memory CD8-positive T cells.³

Interestingly, advanced transcriptomic studies have revealed a paradox: this exhaustion often coexists with markers of immune hyperactivation.¹¹ Single-cell transcriptomic analyses have identified exhaustion-associated CD8-positive T-cell clusters that upregulate specific transcriptional regulators, such as TOX, particularly in severe disease states.¹⁶ These transcriptional changes suggest a paradoxical phenotype where the T cells are simultaneously incapable of executing their primary antiviral functions to clear the virus, yet they remain highly capable of sustaining the damaging, low-grade tissue inflammation that characterizes Long COVID.¹¹ Analogous studies in cancer immunology have demonstrated that T cells can begin exhibiting these exhausted hallmarks within hours of continuous antigen exposure, highlighting how rapidly a severe SARS-CoV-2 infection could push an already stressed HIV-positive immune system into a dysfunctional state.¹⁷

Inflammasome Activation and the Cytokine Storm

The persistent, low-grade inflammation seen in Long COVID is heavily mediated by intracellular innate immune sensors, most notably the NLRP3 inflammasome. An inflammasome is a complex, multiprotein structure found primarily within innate immune cells like macrophages, monocytes, and microglia, which are the resident immune cells of the central nervous system. Its primary biological function is to detect pathogenic microorganisms or signals of cellular damage and, in response, trigger the maturation and release of highly potent pro-inflammatory cytokines.¹⁹

Research has demonstrated that both HIV and SARS-CoV-2 independently possess the ability to activate the NLRP3 inflammasome.¹⁹ During acute COVID-19, SARS-CoV-2-induced activation of the inflammasome within the central nervous system results in profound neuroinflammation. This neuroinflammation is heavily theorized to be the root cause of the myriad neurological manifestations—such as severe cognitive impairment, chronic headaches, and sensory dysregulation—frequently seen in Long COVID patients.¹⁹

Because people living with HIV already harbor a baseline level of inflammasome activation and systemic inflammation due to the retrovirus, the introduction of SARS-CoV-2 initiates a severe compounding effect. Once activated, the inflammasome drives the massive production and release of cytokines, specifically interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha.³ Elevated levels of these specific pro-inflammatory cytokines in the plasma and tissues of discharged patients are strongly predictive of Long COVID development, often persisting alongside impaired oxygen exchange and tissue hypoxia.²⁰

Furthermore, extensive clinical biomarker studies have identified specific cytokine signatures that distinguish people living with HIV who go on to develop Long COVID from those who manage to recover fully. Elevated levels of interferon-gamma-induced protein 10 (IP-10) and tumor necrosis factor-alpha are strongly correlated with Long COVID occurrence in this specific population.⁴ IP-10, in particular, has been isolated in multiple studies as a significant, predictive biomarker strongly associated with persistent Long COVID symptoms uniquely in people living with HIV.³

Conversely, the meta-analyses have shown that decreased levels of interferon-beta are associated with Long COVID. Interferon-beta is a cytokine that typically provides protective antiviral and immunoregulatory functions, such as inhibiting excessive T-cell migration into tissues and upregulating the secretion of calming, anti-inflammatory molecules.⁴ The lack of this protective marker further exposes people living with HIV to prolonged disease states.⁴

Viral Persistence, Compartmentalization, and Reactivation

A leading scientific hypothesis for the fundamental etiology of Long COVID is the failure of the host immune system to fully eradicate the SARS-CoV-2 virus, leading to the establishment of persistent viral reservoirs within specific tissue compartments. This concept of viral persistence is intimately familiar to researchers studying HIV, a virus known for avoiding complete eradication by integrating its genetic material into the host genome and establishing latent reservoirs in long-lived immune cells. While SARS-CoV-2 is an RNA virus that does not integrate into human DNA in the same manner as a retrovirus, emerging evidence indicates it is highly capable of establishing long-term persistence within tissues, continuously provoking the immune system long after the acute respiratory symptoms have faded.¹

Tissue Reservoirs and Continuous Antigenic Stimulation

A growing body of clinical reports, advanced imaging techniques, and post-mortem tissue analyses have provided compelling evidence that SARS-CoV-2 viral RNA and residual viral protein antigens—such as the Spike protein and the Nucleoprotein—can persist in multiple organs for months, or even over a year, after the acute respiratory infection has resolved.¹ These persistent reservoirs have been detected far beyond the respiratory tract, identified within the gastrointestinal tract, brain tissue, tonsils, lungs, heart, and reproductive organs.¹ Even when standard clinical nasopharyngeal swabs return negative results, indicating successful clearance from the upper respiratory tract, the virus may remain active, continuing to translate proteins deep within isolated tissue compartments.¹ A notable study conducted by the Institut Pasteur utilizing non-human primate models demonstrated that SARS-CoV-2 could be found in the lungs of subjects for up to 18 months post-infection, linking this persistence directly to a failure of early innate immunity.²²

For people living with HIV, the risk of establishing and maintaining these SARS-CoV-2 reservoirs is theoretically amplified. The initial, historic HIV infection causes a profound loss and enduring dysfunction of tissue-specific immune cells, particularly within mucosal tissues like the gut.³ This localized, compartment-specific immune impairment reduces the body's overall capacity to efficiently identify and clear SARS-CoV-2 viral genetic material from these areas.³

The continuous, low-level release of viral proteins from these tissue reservoirs serves as a relentless antigenic stimulus to the immune system. This constant provocation is believed to be the primary driver of the T-cell exhaustion described previously. The immune system is locked in a state of chronic engagement, behaving as if it is fighting a continuous active infection.²¹ This exhausts the body's cellular resources while simultaneously inducing localized and systemic inflammation that damages the surrounding healthy organs.¹

One unique, measurable manifestation of this ongoing viral interplay is the clinical observation of increased HIV "viral blips"—transient, low-level spikes in HIV viral load detected in the blood—during the post-acute period of COVID-19. This suggests that the profound immunological disruption and inflammation caused by SARS-CoV-2 may temporarily destabilize the suppression of the HIV reservoir itself, highlighting the complex dynamics between the two distinct pathogens.³

Compromised Surveillance and Herpesvirus Reactivation

The dysfunction of the cellular immune system in people living with HIV also opens the door for the opportunistic reactivation of latent secondary infections, specifically human herpesviruses. A significant proportion of the general global population, and a particularly high percentage of people living with HIV, harbor lifelong latent infections of viruses such as Epstein-Barr virus (EBV), human cytomegalovirus (CMV), and various other herpes simplex viruses.¹ Under normal, healthy physiological circumstances, these viruses are kept in a strict state of dormancy by constant, vigilant surveillance from cytotoxic CD8-positive T cells.

However, because HIV infection intrinsically impairs the overall surveillance capacity of CD8-positive T cells, and because the acute SARS-CoV-2 infection further exhausts these specific immune actors, the immune system's grip on these latent viruses loosens.³ During the post-acute phase of COVID-19, people living with HIV become highly susceptible to the reactivation of EBV and CMV.¹

Serologic evidence indicating recent EBV reactivation—identified through specific antibody testing—has been robustly associated with an increased odds of developing Long COVID.³ The reactivation of these latent herpesviruses acts as an independent biological driver of chronic fatigue, severe neurocognitive impairment, and systemic inflammation. This creates a complex, multi-viral etiology for Long COVID in this vulnerable population, where the symptoms are driven not only by SARS-CoV-2 but by the opportunistic awakening of pre-existing infections.¹

Microbial Translocation and the Gut-Systemic Axis

To fully comprehend the systemic nature of Long COVID, researchers have increasingly turned their attention to the gastrointestinal tract. The human gut is not merely an organ of digestion; it is the largest immunological organ in the body and houses a vast, complex microbiome that plays a critical role in regulating systemic immune health. The physical integrity of the intestinal epithelial barrier is paramount to preventing the trillions of commensal bacteria residing in the gut from entering the sterile bloodstream. The biological intersection of HIV and SARS-CoV-2 wreaks havoc on this delicate gut-systemic axis, driving profound chronic disease.

Intestinal Barrier Disruption

An underlying HIV infection inherently causes profound damage to the gut-associated lymphoid tissue. The chronic cytokine release associated with long-term HIV infection drives persistent localized inflammation in the intestinal tissues. This continuous inflammation physically degrades the tight junction proteins that normally seal the gaps between intestinal epithelial cells.²⁴ This structural degradation leads to increased intestinal permeability, commonly referred to as "leaky gut."

When a person living with HIV is subsequently infected with SARS-CoV-2, the respiratory virus further assaults the gastrointestinal tract. SARS-CoV-2 aggressively binds to angiotensin-converting enzyme 2 (ACE2) receptors, which are highly expressed along the intestinal lining.²⁶ The resulting viral replication within the gut, combined with an acute cytokine surge, attracts inflammatory cells to the area. This amplifies localized tissue damage and further compromises the already weakened epithelial barrier integrity.²⁴

Translocation Biomarkers and Systemic Consequences

With the physical intestinal barrier severely compromised, microbial products and fragments that normally reside safely within the gut lumen leak into the systemic circulation—a pathological process known as microbial translocation.³ This translocation is considered a major mechanistic driver of Long COVID pathogenesis.³

Clinical studies analyzing patients co-infected with HIV and SARS-CoV-2 have identified significantly elevated circulating biomarkers indicating severe microbial translocation. Compared to individuals living with HIV who have never contracted COVID-19, co-infected individuals exhibit markedly higher plasma levels of lipopolysaccharide (LPS).²⁴ Lipopolysaccharide is a potent structural component of certain bacterial cell walls; its presence in the bloodstream is a strong signal of systemic infection. The presence of LPS triggers a massive, widespread immune response, evidenced by correspondingly high levels of soluble CD14 (sCD14), a recognized biomarker of severe monocyte activation.²⁴

Furthermore, researchers have observed the systemic redistribution of zonulin, a key tight-junction protein.²⁴ Elevated levels of zonulin in the blood act as a direct clinical indicator that the gut barrier has failed. High zonulin levels correlate heavily with intestinal CD4-positive T-cell depletion and escalating systemic inflammation.²⁴

Microbiome Dysbiosis and Metabolic Disruption

The physical breach of the gut barrier is accompanied by profound changes in the composition of the microbiome itself. While overarching microbial diversity across the entire gut may remain relatively stable during co-infection, the dual viral presence drives specific, highly detrimental species-level alterations.²⁴

For instance, detailed microbiome sequencing has revealed a significant depletion in the abundance of beneficial bacteria, such as those belonging to the genus Blautia, in patients with severe COVID-19 and HIV co-infection.²⁴ This specific depletion correlates heavily with disease severity and ongoing tissue damage.²⁴ The loss of these beneficial microbes eliminates the production of vital short-chain fatty acids and antimicrobial peptides that the body normally utilizes to suppress inflammation and maintain mucosal homeostasis.²⁶

Conversely, the presence of certain microbial signatures, such as the genus Akkermansia, has demonstrated strong potential as a diagnostic biomarker for identifying the severity of co-infection.²⁴ Ultimately, microbial translocation feeds a vicious, self-sustaining pathological loop: the initial viral infection causes systemic immune activation, which increases gut inflammation. This gut inflammation further damages the intestinal barrier, allowing more bacterial products to leak into the blood, which continuously drives the chronic systemic pathology and fatigue characteristic of Long COVID.²⁵

Microvascular and Endocrine Pathologies

While immunological exhaustion, systemic inflammasome activation, and persistent tissue viral reservoirs form the biological core of Long COVID pathobiology in people living with HIV, these mechanisms ultimately manifest as symptoms through downstream physiological failures. These failures are most notable within the body's vascular and endocrine systems, which govern blood flow and hormonal balance, respectively.

Endothelial Damage, Microclotting, and Hypoxia

The endothelium, the delicate inner lining of the body's blood vessels, is highly vulnerable to both chronic inflammation and direct viral infection. People living with HIV naturally harbor higher baseline levels of endothelial dysfunction due to the ongoing oxidative stress and low-grade inflammation caused by decades of living with a retrovirus.³

During an acute SARS-CoV-2 infection, the virus directly attacks endothelial cells, leading to widespread vascular inflammation, clinically known as endotheliitis. This damage promotes severe microvascular dysfunction, platelet hyperactivation, and the abnormal formation of microscopic blood clots, a phenomenon known as microclotting.³ These microclots can silently obstruct tiny capillaries throughout the entire body, from the lungs to the brain, severely impairing the exchange of oxygen and leading to deep tissue hypoxia.²⁰

This persistent hypoxic state deprives cells of necessary oxygen, forcing cellular metabolism to adapt poorly. This lack of oxygenation contributes directly to the profound, unremitting physical fatigue, muscle pain, and exercise intolerance reported by Long COVID patients. It is also theorized to drive enduring abnormalities in B-cell function.²⁰ For people living with HIV, their pre-existing vascular stress and baseline endothelial damage make the development of these microclots more likely, and their downstream systemic effects more devastating, complicating recovery.³

Adrenal Insufficiency and Hormonal Collapse

The profound, debilitating fatigue, sudden drops in blood pressure, and autonomic nervous system dysfunction characteristic of Long COVID bear a striking clinical resemblance to classic endocrine disorders. This clinical overlap has prompted researchers to deeply investigate the adrenal system. The adrenal cortex, small glands located on top of the kidneys, is responsible for the production of cortisol. Cortisol is a critical steroid hormone that regulates core metabolism, modulates the immune response, and manages the body's reaction to stress. The adrenal cortex is highly vascularized and has been identified as a known direct target site for SARS-CoV-2 infection.³

Clinical studies analyzing Long COVID patients have established a clear biological association between abnormally low cortisol levels and the presence of persistent post-viral symptoms.³ Notably, many people living with HIV in the modern antiretroviral therapy era already exhibit subclinical levels of adrenal insufficiency, meaning their adrenal glands function adequately under normal conditions but may fail under severe stress.³

The direct viral assault on the highly vascularized adrenal glands by SARS-CoV-2, combined with the massive systemic exhaustion of the immune response and localized microvascular clotting, may push this subclinical weakness into full, symptomatic adrenal insufficiency.³ This hormonal collapse is highly likely to be a major biological driver of the severe, unremitting exhaustion and autonomic instability that defines the Long COVID experience for many individuals within this specific population.³

Clinical Management and Integrated Care Models

The multi-systemic complexity of Long COVID presents an unprecedented challenge for global healthcare systems. It necessitates a fundamental paradigm shift in how post-viral syndromes are identified, diagnosed, and managed over the long term. For people living with HIV, standard, siloed clinical approaches are often insufficient. Their care requires highly integrated, multidisciplinary medical models capable of addressing both the baseline chronic HIV infection and the diverse, multi-organ post-acute sequelae of COVID-19.

Overcoming Diagnostic Ambiguity and Identifying Biomarkers

The most fundamental clinical hurdle in managing Long COVID in people living with HIV is the current lack of a definitive, universal diagnostic biomarker that can be assessed via a simple laboratory test.²⁸ Without a clear tool for confirming positive diagnoses, both clinical care and the funding of pharmaceutical trials face significant roadblocks.²⁸ While current research has identified highly promising indicators—such as elevated IP-10, circulating inflammatory proteins like C3, C4, and C5, and specific exhausted T-cell signatures—none of these have yet been translated into a commercially available, standardized blood test.⁴

Consequently, clinical diagnosis currently relies heavily on comprehensive clinical evaluation, patient history, and the careful tracking of patient-reported symptoms. As demonstrated extensively by the data from the RECOVER initiative, clinicians must be exceptionally vigilant against diagnostic overshadowing.⁸ When a patient living with HIV presents to a clinic with new-onset severe fatigue, cognitive impairment, or sudden autonomic dysfunction months after recovering from a COVID-19 infection, clinicians must actively consider Long COVID. They must avoid defaulting to the assumption that the symptoms are simply a natural exacerbation of baseline HIV inflammation, the long-term side-effects of antiretroviral drug regimens, or normal aging.⁴ Furthermore, routine objective laboratory or imaging findings—which frequently return "normal" results in Long COVID patients despite severe subjective symptoms—should not be used as a definitive reason to dismiss a patient's suffering.²⁹

The Necessity of Multidisciplinary and Integrated Care Models

Because Long COVID impacts the nervous, respiratory, digestive, and cardiovascular systems simultaneously, its optimal management requires a highly coordinated response across multiple medical specialties. In response to the crisis, specialized Post-Acute Sequelae of SARS-CoV-2 clinics have emerged. These are largely centralized in major academic medical centers and offer comprehensive care that brings together experts in pulmonology, cardiology, neurology, rheumatology, psychiatry, and physiatry.³⁰

Physiatrists—physicians specializing in physical medicine and rehabilitation—have proven to be particularly effective in leading these interdisciplinary teams. Their training uniquely positions them to adopt a holistic approach focused on functional restoration, symptom management, and coordinating various allied health disciplines such as physical therapy, occupational therapy, and respiratory therapy.³²

Below is a breakdown of various care models identified by health research agencies for managing Long COVID, highlighting the need for diverse approaches to ensure equity ³²:

Model of Care	Key Example	Salient Clinical Features
Specialty-Based Model	Academic Centers (e.g., Johns Hopkins)	Comprehensive, multidisciplinary plan of care; onsite specialists; advanced remote monitoring of vitals for high-risk patients.
Primary Care-Based Model	County Health Systems	Evidence-based guideline approach; utilizes primary care algorithms to manage symptoms and determine indications for specialist referrals.
Home-Based / Telehealth	Virtual Rehabilitation Programs	Low barrier to entry; increases access for underserved or geographically isolated populations; requires high patient motivation.

However, relying solely on specialized academic centers presents a significant barrier for many marginalized populations, potentially exacerbating existing health inequities. Therefore, integrating Long COVID screening and management directly into existing community primary care and HIV-specific clinics is absolutely critical for public health.³²

The World Health Organization (WHO) has strongly recognized the necessity of integrated, person-centered care for people living with HIV. Recent updated WHO guidelines strongly recommend the integration of non-communicable disease management—such as care for diabetes, severe hypertension, and mental health disorders—directly into routine HIV service delivery.³⁴ Because conditions like hypertension and clinical depression share overlapping physiological and inflammatory pathways with Long COVID, this holistic integration ensures that all underlying comorbidities exacerbating the patient's post-viral state are managed simultaneously under one clinical roof.³⁴ Primary care providers managing these complex patients must utilize shared decision-making, setting realistic, achievable care goals focused on symptom mitigation and gradual functional improvement rather than immediate cures.²⁹

Preventative Strategies, Vaccinations, and Future Therapeutics

Currently, preventative public health measures remain the most highly effective strategy against the development of Long COVID. Broad epidemiological data overwhelmingly supports the clinical efficacy of COVID-19 vaccination in mitigating the risk of developing post-acute sequelae.³⁵ Among people living with HIV, breakthrough infections can still occur post-vaccination, and may even cause transient increases in the size of latent HIV reservoirs.²³ However, robust vaccination protocols significantly lower overall mortality rates and dramatically reduce the statistical odds of developing Long COVID following an exposure.³⁵

Looking toward the future of pharmacological intervention, research into the therapeutic use of extended antiviral courses is highly active. Given the strong, accumulating biological evidence supporting the viral tissue reservoir hypothesis, researchers are turning to familiar strategies. Scientists and pharmacologists who spent decades developing life-saving antiretroviral therapies for HIV are now actively investigating whether extended, high-dose combinations of SARS-CoV-2 specific antivirals can successfully eradicate persistent tissue reservoirs in Long COVID patients.²⁸ The strategic hope within the scientific community is that the hard-won lessons from four decades of dedicated HIV research—specifically in understanding viral persistence, navigating chronic inflammation, and developing multi-drug antiviral regimens—can be leveraged to accelerate the discovery of targeted, effective therapies for Long COVID.²⁸

Conclusion

The intersection of the ongoing human immunodeficiency virus and SARS-CoV-2 pandemics has generated a profoundly complex clinical entity that severely tests the current limits of modern immunology, virology, and clinical care. The data indicates clearly that people living with HIV are not merely experiencing the simple additive effects of contracting two distinct viruses; rather, they are being subjected to a powerful, synergistic biological assault. The baseline immune dysregulation and chronic systemic inflammation inherent to a lifelong HIV infection provide a highly fertile biological ground for SARS-CoV-2. The novel respiratory virus exploits this environment to induce profound, rapid T-cell exhaustion, hyperactivate innate inflammatory sensors like the NLRP3 inflammasome, and establish persistent, active viral reservoirs within compromised tissue compartments. Furthermore, the exacerbation of gut barrier dysfunction drives continuous microbial translocation, creating an unyielding cycle of systemic inflammation, microvascular clotting, and endocrine disruption.

The epidemiological evidence is unambiguous and alarming: people living with HIV face a substantially elevated, distinct risk of developing Long COVID. This condition affects nearly every major organ system, carrying profound neurocognitive, respiratory, and physical implications. Addressing this compounding public health crisis requires a heightened state of clinical vigilance to overcome the persistent issue of diagnostic overshadowing, recognizing that new chronic symptoms in this population are often distinct post-viral sequelae requiring specific interventions. Moving forward, the successful management of Long COVID in people living with HIV will depend heavily on the rapid expansion of holistic, multidisciplinary care models that are integrated directly into community primary care and HIV-specific healthcare settings. Ultimately, unraveling the precise biological mechanisms of viral persistence and immune exhaustion in this uniquely vulnerable demographic will not only alleviate their specific, heavy burden, but may also provide the critical, foundational biological insights necessary to eventually cure Long COVID in the broader global population.

Works cited

1. Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12568064/

2. HIV infection linked to increased risk of long COVID - CIDRAP, accessed February 20, 2026, https://www.cidrap.umn.edu/hivaids/hiv-infection-linked-increased-risk-long-covid

3. Long COVID in people living with HIV - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10167544/

4. Long COVID among people with HIV: A systematic review and meta‐analysis - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11725417/

5. Long COVID Between People With and Without HIV: a Statewide ..., accessed February 20, 2026, https://pubmed.ncbi.nlm.nih.gov/41636553/

6. Sharon Weissman's research works | University of South Carolina and other places, accessed February 20, 2026, https://www.researchgate.net/scientific-contributions/Sharon-Weissman-2042797556

7. Long COVID among people with HIV: A systematic review and meta-analysis - PubMed, accessed February 20, 2026, https://pubmed.ncbi.nlm.nih.gov/39252604/

8. HIV Infection and Long COVID: A RECOVER Program, Electronic ..., accessed February 20, 2026, https://pubmed.ncbi.nlm.nih.gov/40354184/

9. HIV infection and Long COVID: A RECOVER Program, electronic health record based cohort study, accessed February 20, 2026, https://recovercovid.org/publications/hiv-infection-and-long-covid-recover-program-electronic-health-record-based-cohort

10. POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION | medRxiv, accessed February 20, 2026, https://www.medrxiv.org/content/10.1101/2022.02.10.22270471v2.full

11. T-cell exhaustion in COVID-19: what do we know? - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12605343/

12. Simulating CD8 T cell exhaustion: A comprehensive approach - PMC - NIH, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12268933/

13. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2 - PubMed, accessed February 20, 2026, https://pubmed.ncbi.nlm.nih.gov/38212464/

14. Study Links Long COVID to Lasting Inflammation and Immune Exhaustion, accessed February 20, 2026, https://www.autoimmuneinstitute.org/covid_timeline/study-links-long-covid-to-lasting-inflammation-and-immune-exhaustion/

15. Long COVID involves activation of proinflammatory and immune exhaustion pathways, accessed February 20, 2026, https://recovercovid.org/publications/long-covid-involves-activation-proinflammatory-and-immune-exhaustion-pathways

16. T-cell exhaustion in COVID-19: what do we know? - Frontiers, accessed February 20, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1678149/full

17. Study finds hallmarks of T cell exhaustion within hours of tumor exposure | ScienceDaily, accessed February 20, 2026, https://www.sciencedaily.com/releases/2023/08/230803112958.htm

18. Study finds hallmarks of T cell exhaustion within hours of tumor exposure - Vanderbilt Health, accessed February 20, 2026, https://news.vumc.org/2023/08/03/study-finds-hallmarks-of-t-cell-exhaustion-within-hours-of-tumor-exposure/

19. The Impact of COVID-19 on People Living with HIV-1 and HIV-1-Associated Neurological Complications - MDPI, accessed February 20, 2026, https://www.mdpi.com/1999-4915/15/5/1117

20. Pathophysiological, immunological, and inflammatory features of long COVID - Frontiers, accessed February 20, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1341600/full

21. Why viral reservoirs are a prime suspect for long COVID sleuths | EATG, accessed February 20, 2026, https://www.eatg.org/hiv-news/why-viral-reservoirs-are-a-prime-suspect-for-long-covid-sleuths/

22. COVID-19: the persistence of SARS-CoV-2 in the lungs and the role of innate immunity |, accessed February 20, 2026, https://www.pasteur.fr/en/press-area/press-documents/covid-19-persistence-sars-cov-2-lungs-and-role-innate-immunity

23. Effect of SARS-CoV-2 Breakthrough Infection on HIV Reservoirs and T-Cell Immune Recovery in 3-Dose Vaccinated People Living with HIV - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10748120/

24. Gut microbiota alterations and microbial translocation in ... - Frontiers, accessed February 20, 2026, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2026.1688580/full

25. I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9411647/

26. Microbiome and Long COVID-19: Current Evidence and Insights - MDPI, accessed February 20, 2026, https://www.mdpi.com/1422-0067/26/20/10120

27. Gut microbiome-based strategies for HIV prevention and therapy, current challenges and future prospects - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12874720/

28. Important long-COVID lessons from AIDS researchers - European AIDS Treatment Group, accessed February 20, 2026, https://www.eatg.org/hiv-news/important-long-covid-lessons-from-aids-researchers/

29. Long COVID Clinical Guidance - CDC, accessed February 20, 2026, https://www.cdc.gov/long-covid/hcp/clinical-guidance/index.html

30. Between Chronic Inflammation and Long COVID - National Cancer Institute, accessed February 20, 2026, https://epi.grants.cancer.gov/events/inflammation-long-covid/LongCovidWorkshop_ProgramBook_RELEASE_508_2023_v1.pdf

31. Integrated Care Models for Long Coronavirus Disease - PubMed, accessed February 20, 2026, https://pubmed.ncbi.nlm.nih.gov/37419540/

32. Integrated Care Models for Long Coronavirus Disease - PMC, accessed February 20, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10165471/

33. Long COVID Models of Care I. Background and Objectives for the Technical Brief, accessed February 20, 2026, https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/long-covid-protocol.pdf

34. WHO released updated guideline on HIV service delivery, accessed February 20, 2026, https://www.who.int/news/item/12-09-2025-who-released-updated-guideline-on-hiv-service-delivery

35. HIV Infection is Associated with Higher Risk of Post-Acute Sequelae of SARS-CoV-2 (PASC) However Vaccination is Protective - NATAP, accessed February 20, 2026, https://www.natap.org/2023/HIV/122823_03.htm

36. Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study - PubMed, accessed February 20, 2026, https://pubmed.ncbi.nlm.nih.gov/38318191/

37. Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study - Frontiers, accessed February 20, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1297195/full

38. Targeting the SARS-CoV-2 reservoir in long COVID | ESWI, accessed February 20, 2026, https://eswi.org/education-hub/targeting-sars-cov-2-reservoir-long-covid